Intellia Prices $180M Stock Offering at $10.75/Share to Fund Lonvo-z BLA and Commercial Launch

Intellia Therapeutics announces the pricing of its underwritten public offering of common stock: 16,744,187 shares at $10.75 per share, generating gross proceeds of approximately $180 million. Underwriters (Jefferies, Goldman Sachs, Citigroup) hold an option to purchase up to 2,511,628 additional shares. ARK Investment Management (Cathie Wood) separately disclosed purchasing approximately 596,000 shares on April 28, 2026 at market. Net proceeds will be used to fund the rolling BLA submission to the FDA for lonvo-z (lonvoguran ziclumeran) for hereditary angioedema, pre-commercial and commercial buildout activities, and ongoing clinical pipeline work including the Phase 3 MAGNITUDE trial of lonvo-z for ATTR cardiomyopathy. The offering represents an important signal of capital market confidence in CRISPR's commercial viability following the first-ever positive Phase 3 readout for an in vivo gene editing therapy two days prior.